Phase 2 Open-Label Extension

Ongoing Phase 2 Open-Label Dermatomyositis Study

Corbus received approval for an open-label extension to its single center, double-blind, randomized, placebo-controlled Phase 2 clinical study of lenabasum for dermatomyositis from the U.S. Food and Drug Administration (FDA) in November 2016. Nearly all the participants from the double-blind portion of the study volunteered to enroll for the long-term open-label extension. The goal of the open-label extension study is to collect long-term safety and efficacy data on lenabasum.

For more information, contact:

DM patients contact: DMpatients@corbuspharma.com
Physicians contact: DMphysicians@corbuspharma.com
Other inquiries: info@corbuspharma.com

Site Contact Principal Investigator

University of Pennsylvania Perlman School of Medicine

3400 Civic Center Blvd
Philadelphia, PA 19104
United States

Victoria Werth, MD

215-898-0168
werth@mail.med.upenn.edu

Victoria Werth, MD